Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
复制标题
获得性免疫缺陷综合征 (AIDS) 中的人类免疫缺陷病毒 (HIV) 抗原血症 (p24) 以及齐多夫定 (AZT) 治疗的效果。
DOI：
10.7326/0003-4819-108-2-175
复制
发表时间：
1988
影响因子：
39.2
通讯作者：
Eugene E. Emeson
中科院分区：
文献类型：
--
作者：
George Gee Jackson;D. Paul;Lawrence A. Falk;M. Rubenis;Joanne C. Despotes;David Mack;M. Knigge;Eugene E. Emeson
人类免疫缺陷病毒（HIV）感染可引起病毒抗原血症，主要检测为p24病毒核心蛋白。在16例获得性免疫缺陷综合征（AIDS）或AIDS相关综合征患者中，12例患者血浆中的抗原血症范围为16至3006 pg/mL。水平可分为高（大于100 pg/mL）或低（15至65 pg/mL）。3例抗p24抗体阳性患者无抗原血症。齐多夫定（AZT），每4小时200或250毫克，减少抗原血症约90%;其他方案效果较差。白细胞培养阳性艾滋病毒的患者抗原血症，并在三分之一的样本中，在没有抗原血症。高水平的抗原血症与症状、CD 4细胞计数和预后相关。需要较低剂量的药物毒性随后是抗原血症增加、症状复发和CD 4细胞减少，表明淋巴细胞毒性。监测抗原血症可用于评估HIV感染患者和评估抗病毒化疗的效果。
Infection with human immunodeficiency virus (HIV) may cause viral antigenemia, detected primarily as p24 viral core protein. Among 16 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex studied serially, 12 had or developed antigenemia ranging from 16 to 3006 pg/mL in plasma. The level could be categorized as high (greater than 100 pg/mL) or low (15 to 65 pg/mL). Three patients with anti-p24 antibody had no antigenemia. Zidovudine (AZT), 200 or 250 mg every 4 hours, reduced antigenemia by about 90%; other regimens were less effective. Leukocyte cultures were positive for HIV from patients with antigenemia, and in one third of samples in the absence of antigenemia. High levels of antigenemia correlated with symptoms, CD4 cell count, and prognosis. Drug toxicity requiring a lower dose was followed by increased antigenemia, recurrent symptoms, and decreased CD4 cells, suggesting lymphocyte toxicity. Monitoring antigenemia can be useful in evaluating patients with HIV infection and in evaluating the effect of antiviral chemotherapy.